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ABSTRACT 
Background 
Oxidative stress is a detrimental feature of diabetes implicated in the 
progression of the disease and its complications. The relationship between 
insulin therapy and oxidative stress is complex. This study tested the 
hypothesis that improved glucose control, rather than insulin dose, is central to 
reduced oxidative stress in patients with type 2 diabetes following continuous 
subcutaneous insulin infusion (CSII). 
Methods 
In this 16-week, multicentre study, 54 CSII-naïve patients with type 2 diabetes 
(age 57±10y, HbA1C 69 ±15 mmol/mol [8.5±1.4%], diabetes duration 13±6y) 
treated with either oral antidiabetic agents (OAD) alone (n=17), basal insulin 
±OAD (n=17) or multiple daily injections (MDI) ±OAD (n=20) were the 
evaluable group. Diabetes medications except metformin were discontinued, 
and 16 weeks of CSII was initiated. Insulin dose was titrated to achieve optimal 
glycemic control. A plasma marker of oxidative stress relevant to 
cardiovascular disease (oxidized low density lipoprotein [ox-LDL]) was 
assessed at baseline and week 16. 
Results 
CSII improved glycemic control (HbA1C -13±2 mmol/mol [-1.2±0.2%]; fasting 
glucose -36.6±8.4 mg/dL; mean glucose excursion -23.2±6.5 mg/dL, 
mean±SE; all P<0.001) and reduced ox-LDL (-10.5%; P<0.05). The 
antioxidant effect was cohort-independent (P>0.05), but was significantly more 
pronounced in patients on statins (P=0.019). The effect of CSII was more 
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closely correlated to improvements in glucose excursion (P=0.013) than to 
insulin dose (P>0.05) or reduction in HbA1C (P>0.05).  
Conclusions 
CSII induces depression of plasma ox-LDL associated with change in glucose 
control, rather than with change in insulin dose. The effect is augmented in 
patients receiving statins.  
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INTRODUCTION 
The incidence of type 2 diabetes is increasing rapidly and, with it, the 
requirement for insulin therapy in advanced disease.1 Poor glycemic control, as 
measured by glycated haemoglobin (HbA1C), has long been linked to mortality 
associated with diabetes2 and improvement in control is associated with 
reduced complications.3 However, intensive therapy to achieve near-normal 
HbA1C levels in patients with type 2 diabetes has not been shown to reduce 
cardiovascular events3, 4 and is associated with a rise in all-cause mortality.4 
The link between diabetes and vascular disease is complex, but oxidative 
stress, mediated by increased prevalence of harmful reactive oxygen species 
(ROS), is associated with type 2 diabetes and has been implicated both in its 
progression via β-cell dysfunction and with macro- and microvascular diabetes 
complications.5-7 There is a close relationship between plasma-borne markers 
of oxidative stress (e.g. oxidized low density lipoprotein [ox-LDL]) and risk of 
coronary artery disease and stroke.8, 9 The origins of oxidative stress associated 
with type 2 diabetes are complex,10 with mitochondrial dysfunction induced by 
hyperglycemia and/or excessive glycemic excursions11, together with advanced 
glycated end products (AGEs)12 and inflammation, all contributing to the 
effect. It follows that improved glycemic control would be expected to reduce 
oxidative stress, a feature that might play an important role in reducing the rate 
of progression of β-cell dysfunction as well as improving cardiovascular 
outcomes. Basal or basal-bolus continuous subcutaneous insulin infusion 
(CSII; <0.04 unit/kg/day) has been shown to have a significant antioxidant 
effect in patients with type 2 diabetes, although the beneficial effect was lost in 
patients treated with higher insulin doses (>0.4 unit/kg/day)13 – the complexity 
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of the association prompted the authors of that study to indicate the need for 
further study. 
The benefits of CSII are well established in patients with type 1 diabetes.14 In 
type 2 diabetes, studies assessing CSII versus multiple daily injection therapy 
have generally demonstrated similar improvements in overall glycemic control 
(as measured by HbA1C),
15, 16 with some studies showing superior postprandial 
glucose control with CSII.16, 17  
In previously published findings of the present16-week study, CSII in patients 
with type 2 diabetes was found to be preferred to patients’ previous treatment 
regimens18 and to significantly improve both HbA1C and self-monitored 7-point 
glucose profiles.19, 20 The aim of the present post-hoc analysis of samples from 
the same study was to test the hypothesis that these benefits in glycemic 
control were reflected in depression of markers of oxidative stress. 
 
METHODS 
Sample size 
A sample size of 20 patients in each cohort was estimated to produce a 90% 
confidence interval equal to the sample mean with a precision of 0.44 with an 
estimated standard deviation of 1.2, with respect to HbA1C. 
 
Patients 
Fifty-eight patients with type 2 diabetes treated with oral antidiabetic agents 
(OAD), with or without insulin enrolled in the study at 6 US study sites 
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between March & December 2008. Approval was obtained from local ethics 
committees prior to commencement of the study. Written consent was received 
from all patients taking part in the study, which complied with the Declaration 
of Helsinki and its amendments.  
 
Enrolled patients were men and women 18-75 years old with type 2 diabetes 
(HbA1C 53-91 mmol/mol [7.0-10.5%]) and with undetectable anti-glutamic 
acid decarboxylase antibodies. Exclusion criteria included prior CSII, women 
who were pregnant, lactating or planning pregnancy, as well as patients with 
evidence of cardiovascular disease within the last year, including myocardial 
infarction, stroke, arterial revascularization and/or angina with ischemic 
changes on ECG at rest, changes on graded exercise test, or positive cardiac 
imaging test results. Subjects with a past history of cardiovascular events (>1 
year from screening) were enrolled if the subject had been stable for at least 6 
months and, in the investigator’s opinion, the history of cardiovascular disease 
would not affect successful completion of the study and/or personal well-being. 
 
Eligible patients were assigned to one of three cohorts defined by their 
therapeutic regimen at baseline: stable regimen of two or more OAD agents 
(OAD cohort, n=18); basal insulin with or without OAD (basal cohort, n=18) 
or basal-bolus insulin therapy by multiple daily injections (MDI) of insulin 
with or without OAD (MDI cohort; n=22). One patient (MDI cohort) withdrew 
consent, one patient (OAD cohort) did not complete the study (adverse event of 
severe coronary artery disease), one patient (MDI cohort) was withdrawn from 
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the study and one patient (MDI) was lost to follow up; the data for these 
individuals have been excluded from the analysis throughout, leaving a total 
evaluable population of 54 patients, of which samples were available for 53 
patients for oxidative stress measures. Complete sample sets were available for 
50 patients for glucose excursion measures, 51 patients for mean glucose 
measures and 52 patients for HbA1C and fasting plasma glucose measures.   
  
 
Protocol 
Details of the study protocol have been previously reported.19 In brief, patients 
entering the study were withdrawn from all antidiabetic medications except 
metformin for the duration of the study. Sixteen weeks of CSII (Animas® 2020 
insulin pump, Animas Corp, West Chester, PA, USA) was initiated  using 
insulin glulisine (Sanofi Aventis, Bridgewater, New Jersey, USA) with one 
daily basal rate (50% of total daily dose) and insulin boluses (50% of total 
daily dose) split across each major meal. The initial recommended total daily 
insulin dose was 0.5 U/kg body weight. Investigators assessed insulin dosing at 
frequent study site visits, with a target of safely achieving fasting plasma 
glucose concentrations between 70-130 mg/dL and 1.5-2 h postprandial 
glucose values below 180 mg/dL. 
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Measurements 
HbA1C was measured in fresh blood samples at baseline and weeks 4, 8, 12 and 
16 (Covance Laboratory, Indianapolis, IN, USA). The data relating to these 
measures have been reported elsewhere.18-21 
 
Continuous glucose monitoring (CGM) was conducted using the DexCom 
seven system. CGM was implemented for 5-7 days prior to Day 1 of CSII 
(baseline), and for 5-7 days prior to Visit 11 (Week 16). Glucose values from 
the CGMs were downloaded via USB cable at the study site using the DexCom 
DM2 Software application (monitor-specific software). The mean percent of 
CGM blood glucose measurements within the following glucose value ranges 
was summarized: <70 mg/dL, ≥70 mg/dL to ≤140 mg/dL, >140 mg/dL, ≥70 
mg/dL to ≤180 mg/dL, and >180 mg/dL. Data are shown as % time spent with 
blood glucose between 70mg/dL and 140 mg/dL, as an indicator of tight 
glucose control and absence of substantial excursion in either direction. 
 
Fasted venous blood samples were drawn from the antecubital fossa (~60 ml) 
into EDTA tubes for separation of plasma, and blank tubes for separation of 
serum, at baseline and week 16. Samples were immediately centrifuged; 
aspirated plasma and serum was frozen and stored below -70oC for subsequent 
analyses. 
Laboratory analyses 
Plasma oxidized low density lipoprotein (ox-LDL) was selected for this study 
on the basis that it is not only a marker of oxidative stress, but is also implicit 
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in cardiovascular disease development. Ox-LDL was measured using a 
commercially available kit (Oxidized LDL competitive ELISA, Mercodia; 
Salem, NC, USA). Measurements were conducted on samples from baseline 
and week 16.  
 
Statistical analysis 
Data were compared using Student’s t-tests, one way and two-way ANOVA 
with Bonferroni post-tests, and using Pearson’s correlations. P<0.05 was 
considered statistically significant, except for correlation data, where P<0.0167 
was considered significant to correct for multiple comparisons. 
Underlying research materials can be requested from the corresponding author. 
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RESULTS 
Patient characteristics  
Baseline patient demographics and characteristics are shown in table 1. There 
were no significant differences between the cohorts. Approximately 90% of 
patients were treated with metformin at baseline – this treatment was continued 
throughout the study.  
 
Impact of CSII on glucose control and ox-LDL: collated data 
from all three cohorts 
HBA1C, fasting glucose, mean glucose and mean postprandial glucose 
excursion all declined significantly from baseline after 16 weeks of CSII 
(Table 2). Similarly, plasma ox-LDL was significantly depressed after 16 
weeks of CSII compared to baseline (Table 2).  
 
Analysis of data by study cohort 
There was no significant difference in effect of 16 weeks of CSII on HbA1C 
(P=0.51), mean plasma glucose (P=0.98), fasting plasma glucose (P=0.80) or 
mean glucose excursion (P=0.70; all statistics are one-way ANOVAs between 
OAD, basal and MDI cohorts). There was no significant difference in plasma 
concentrations of ox-LDL between the cohorts at baseline (P=0.86); the extent 
of effect of CSII on ox-LDL was not significantly different between the three 
cohorts (Fig 1A; P=0.50).  
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Effect of statin therapy on ox-LDL: collated data from all three cohorts 
Sub-group analysis of the data with respect to statin therapy indicated that there 
was no difference between ox-LDL at baseline in those patients receiving 
statins (n=22) compared to those not receiving statins (n=31;  P=0.21, data not 
shown). However, 16 weeks of CSII induced a significantly greater reduction 
in ox-LDL in patients treated with statin therapy compared with those not 
receiving statin therapy (P=0.019; paired Student’s  t-test; Figure 1B).  
 
Association between ox-LDL and changes in insulin dose, HBA1C 
or tight glucose control 
There was no correlation between change in ox-LDL and either change in 
insulin dose (Figure 2A) or change in HbA1C (Fig 2B) over the 16 week CSII 
period. However, there was a significant negative correlation between change 
in ox-LDL and change in the time spent between 70-140 mg/dL glucose, as 
measured by CGM in week 1 and week 15 (Fig 2C). 
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DISCUSSION 
This study, involving 16 week CSII in patients with type 2 diabetes, shows the 
therapy to reduce HbA1C and to improve glycemic control, irrespective of 
whether patients were treated with OAD, basal insulin or MDI prior to starting 
CSII; there was no difference in any of the plasma markers between the patient 
cohorts at baseline. CSII significantly reduced plasma ox-LDL concentrations; 
the depression in plasma ox-LDL correlated with improved glucose control 
(reduced glucose excursions), but not with insulin dose. 
Baseline characteristics of the patients showed remarkable equivalence across 
the OAD, basal insulin and MDI cohorts. Of the parameters measured, only 
total insulin dose showed a predictable difference between the cohorts (nil in 
OAD and highest in MDI). Importantly, plasma ox-LDL was not different at 
baseline in the three cohorts. This result varies from a previous study 
comparing oxidative stress in patient groups under different treatment 
regimens, 13 but a direct comparison between the studies is not appropriate 
because there were considerable differences in the patient populations in the 
two studies: those in the current study were generally younger, had diabetes for 
a shorter period, had a lower BMI, did not have clinical symptoms of 
cardiovascular disease in the past year and had lower HbA1C at the outset of the 
study. Furthermore, the current study defined the insulin-treated cohorts by 
insulin regimen (basal v MDI), as opposed to total daily insulin dose, and 
measured a plasma marker of oxidative stress (ox-LDL), instead of urinary 
isoprostanes. Therefore, the current findings do not challenge the results or 
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conclusions of the previous report; indeed, they serve to endorse the conclusion 
that the relationship between insulin therapy and oxidative stress is highly 
complex, depending not only on insulin dose and mode of delivery, but also on 
a wide range of patient characteristics. 
Transfer of patients to CSII had a significant effect on glycemic control, as 
determined by HbA1C, mean fasting and postprandial glucose concentrations, 
and pre- to post-meal glucose excursions. The effect was similar in all three 
cohorts for each of these measures, which is not surprising, given that insulin 
dosing was adjusted to achieve similar fasting and postprandial glucose targets.  
Given the well-documented role of oxidative stress in driving progression of 
type 2 diabetes22 and in mediating the macrovascular complications that are 
associated with the disease,5, 7 modulation of oxidative stress represents an 
important target for therapeutic intervention. Hyperglycemia and glucose 
excursions are at the core of the oxidative stress process, instigating 
mitochondrial dysfunction and generation of AGEs - prime sources of harmful 
ROS.12 The downstream link to cardiovascular disease is driven by a 
combination of the essential step of ROS-mediated oxidation of LDL in the 
atherogenic process and the deleterious effect of ROS on endothelial cell 
survival, function and ability to generate bioavailable, protective, nitric oxide 
(NO).10  
Our findings clearly indicate that CSII causes a substantial depression of 
plasma ox-LDL, a key mediator and predictor of cardiovascular disease.23 
CSII-mediated depression of this marker might prove to be beneficial in 
reducing cardiovascular risk in this patient group. The extent of the depression 
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in ox-LDL seen in the current study is similar to that reported for introduction 
of a multiple insulin injection regimen to previously insulin naïve patients (-
15%). 24  
Cohort sub-analysis of the current data revealed that, whilst CSII induced an 
overall reduction in ox-LDL, there was no statistical difference between the 
effect in different cohorts, although those previously on basal insulin showed 
an apparent increase in this marker of oxidative stress. A previous study25 had 
shown that gliclazide reduced a number of markers of oxidative stress 
compared to glibenclamide, but we excluded this as a potential confounder in 
our study because no patients were on gliclazide at recruitment and 
sulphonylureas were withdrawn at the start of the study.  Statin therapy 
represents a possible confounder in the current study because previous work 
has shown that atorvastatin has a profound effect on plasma ox-LDL (-24%),26 
raising the possibility that those patients on statins might be less exposed to 
oxidative stress and, therefore, less affected by CSII in this regard. Sub-group 
analysis of the data from the current study, however, indicated that there was a 
significantly larger effect of CSII on ox-LDL in those patients receiving statin 
therapy. This finding raises the intriguing possibility of a synergistic effect 
between CSII and statins that would need to be confirmed and explored further. 
Given the previous finding that insulin dose might be important in driving the 
extent of oxidative stress,13 it is important to consider this parameter in our 
study. However, we found that there was no correlation between total insulin 
dose and plasma ox-LDL, suggesting that the antioxidant effect of insulin was 
independent of the insulin dose. Instead, it was clear that there was an 
association between the extent to which blood glucose control was improved 
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and the reduction in plasma ox-LDL. This is the principal finding of the study 
because, coupled with the lack of association between HbA1C and ox-LDL after 
CSII, it implies that glucose excursion rather than glycemia per se is the key to 
determining the extent of plasma LDL peroxidation. This finding corresponds 
with those relating to other therapies for glucose control27, 28 and to the 
suggestion that there is a link between glucose variability and oxidative stress29 
and glucose variability and atherogenic potential30, 31 that might be worth 
considering alongside HbA1c as an indicator of risk.  
From a therapeutic perspective, this study indicates that switching from MDI to 
CSII offers a reduced oxidative stress profile, at least over a 16 week period; a 
direct parallel group study would need to be conducted to determine whether 
CSII offers an attractive alternative to MDI on this count. A similar 
improvement might also be realized in patients on OAD, although it is 
recognized the concept of transferring patients direct from OAD to CSII is an 
unlikely scenario in practice. The same benefits might not, however, be 
achieved for those already receiving basal insulin, a result that resonates with 
the lack of benefit seen with basal insulin with respect to cardiovascular 
outcomes.32 Nevertheless, improved glycemic control during daytime and 
reduced postprandial excursions in response to basal insulin could have other 
beneficial effects with respect to outcomes in this patient group. 
 
Study Limitations  
The major limitation of this study is the lack of a parallel control group, which 
would be important for any follow-up study. However, the lack of a control 
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group does not impact on the between-cohort differences or the correlations 
found. At present we can only surmise that the effects on ox-LDL are in 
response to intensive insulin therapy, rather than to CSII per se, although the 
impact seen in the cohort formerly on MDI hints at a unique effect of CSII, but 
this would need to be tested in a study designed specifically for that purpose. 
This was a relatively small study but nevertheless had sufficient power to 
establish an association between tight glucose control and ox-LDL – a larger 
study is warranted to fully explore the possibility of an association between 
CSII-induced changes in glucose control and markers of oxidative stress. In 
addition, the retrospective nature of the study represents a limitation in that 
only baseline and 16 week samples were available for measurement of ox-
LDL; it would be interesting to establish the time course of the reduction and to 
determine the acute impact of glucose excursion in the postprandial period. 
Whilst the participants were well-matched across the cohorts, it is likely that 
those patients already receiving insulin have more advanced disease (higher 
insulin requirements likely reflecting greater -cell failure), irrespective of the 
fact that they have not necessarily been diagnosed with the disease for longer. 
 
Conclusion 
Implementation of CSII in type 2 diabetes is a contentious issue, with 
conflicting evidence from several trials as to its relative merits in this setting 
compared to MDI regimens.15, 16, 33 The results from our study suggest that 
CSII might be a useful tool in reducing the consequences of type 2 diabetes by 
helping to break the oxidative stress link to advanced disease and 
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cardiovascular complications. This open-label, uncontrolled study suggests that 
CSII not only improves glycemic control in patients with type 2 diabetes, 
irrespective of their pre-pump therapeutic regimen, but also has the additional 
benefit of reducing ox-LDL, an important player in the atherosclerotic process. 
This benefit is associated with a reduction in glucose excursion rather than 
insulin dose or HbA1C. Taken together, the findings suggest that a head-to-head 
assessment of CSII and MDI with respect to oxidative damage and, ultimately, 
cardiovascular outcome, is merited in patients with type 2 diabetes. 
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Trial Registration 
This study has clinical trial registration number NCT00922649 at 
ClinicalTrials.gov. 
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TABLES 
Table 1. Baseline demographics, characteristics and drug regimens at 
recruitment.  
 OAD cohort Basal cohort MDI cohort All cohorts 
Intention to treat population (n) 18 18 22 58 
Evaluable population (n) 17a 17b 20c 54 
Male:female (n) 11:6 7:10 9:11 27:27 
Age (y) 57±7 55±8 57±13 57±10 
Diabetes duration (y) 11±6 14±6 15±6 13±10 
Weight (Kg) 105±20 96±16 98±20 99±19 
BMI (Kg/m2) 35±5 34±5 34±5 34±5 
Systolic BP (mmHg) 129±14 125±15 129±18 128±16 
Diastolic BP (mmHg) 77±9 73±11 75±10 75±10 
Triglycerides (mmol/L) 3.2±2.0 2.2±1.2 2.1±1.5 2.5±1.7 
LDL (mmol/L) 2.6±0.8 2.7±1.1 2.6±0.9 2.6±0.9 
Total daily pre-pump insulin (Units) N/A 31.5±19.7††† 99.2±65.3 85.1±35.1 
On-pump total daily insulin at day 1 
(Units) 
41.7±11.7## 36.7±12.0*** 70.9±36.9 51. ±28.7 
On-pump daily insulin at week 16 
(Units) 
46.4±43.9 30.6±16.3 51.9±48.3 43.5±39.8 
Cigarette smokers (n) 1 0 1 2 
Long-acting insulin analogue (n) 0 17 19 36 
Rapid acting insulin analogue (n) 0 0 20 20 
Intermediate acting insulin (n) 0 0 3 3 
Regular human insulin (n) 0 0 1 1 
Metformin (n) 18 15 16 49 
Sulfonylurea (n) 16 6 4 26 
Thiazolidinedione (n) 8 4 4 16 
Exenatide (n) 3 8 1 12 
DPP-4 inhibitor (n) 0 1 0 1 
Meglitinide (n) 0 1 0 1 
Pramlintide (n) 0 0 1 1 
Statin therapy (n) 9 5 8 22 
 
††† P<0.001 basal v MDI, one-way ANOVA with Bonferronni post-test; ##P<0.01 
OAD v MDI; ***P<0.001 basal v MDI. There were no other statistical 
differences between the cohorts with respect to the above parameters. 
Continuous data in this table are expressed as mean±SD. a1 patient did not 
complete; b1 patient withdrawn (investigator decision); c1 patient withdrew 
consent, one patient lost to follow-up. dExcludes OAD in all cohort data.   
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Table 2: Measures of glucose control, oxidative stress (ox-LDL): collated data 
for all cohorts. Data are expressed as mean±SE. 
Measure n Baseline 16 weeks P Change 
(value) 
Change 
(% 
baseline) 
HbA1C (mmol/mol) 
 HbA1C (%) 
52 68±2 
8.4±0.18 
55±1 
7.2±0.13 
<0.0001 13±2- 
1.2±0.2 
-14.2 
Fasting plasma glucose (mg/dL) 52 166.9±7.3 130.3±4.8 <0.0001 -36.6±8.4 -21.9 
Mean plasma glucose (mg/dL) 51 177.5±5.2 152.2±4.4 0.0003 -25.4±6.5 -14.3 
Mean daily postprandial glucose 
excursion (mg/dL) 
50 38.5±5.1 15.3±5.9 0.0008 -23.2±6.5 -60.3 
Ox-LDL (U/L) 53 85.1±35.1 76.2±31.7 0.033 -8.9±4.1 -10.5 
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Figure Legends 
Fig 1. Sub-group analysis of CSII-induced change in ox-LDL by (A) cohort 
and (B) statin therapy. There was no significant difference between the cohorts 
(P=0.50, one-way ANOVA), but there was a significant difference between the 
effect in patients receiving statins and those not (P=0.019).  
Fig 2: A. Association between (A) change in ox-LDL and change in daily 
insulin dose and, (B) change in ox-LDL and change in HbA1C and (C) change 
in ox-LDL and change in % time spent with glucose >70<140 mg/dL 
(measured during week 15 by continuous glucose monitoring).  
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